Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Gautschi

Showing results (21-30 of 91) with videos related to

Pageof 10
Sort By:
Lung Cancer (Amsterdam, Netherlands)|July 4, 2016
MicroRNA-106a targets autophagy and enhances sensitivity of lung cancer cells to Src inhibitorsSacha I Rothschild, Oliver Gautschi, Jasmin Batliner, et al.
Future Oncology (London, England)|February 5, 2014
Crizotinib inhibits migration and expression of ID1 in MET-positive lung cancer cells: implications for MET targeting in oncologyEmanuel Stutz, Oliver Gautschi, Martin F Fey, et al.
Clinical Lung Cancer|May 8, 2009
Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer: current status and new directionsOliver Gautschi, Philip C Mack, Angela M Davies, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2008
Aurora kinases as anticancer drug targetsOliver Gautschi, Jim Heighway, Philip C Mack, et al.
Lung Cancer (Amsterdam, Netherlands)|August 17, 2010
The stem cell gene "inhibitor of differentiation 1" (ID1) is frequently expressed in non-small cell lung cancerSacha I Rothschild, Andreas Kappeler, Daniel Ratschiller, et al.
Swiss Medical Weekly|February 14, 2023
Overall survival and role of programmed death ligand 1 expression in patients with metastatic non-small-cell lung cancer and immunotherapy: an observational study from central SwitzerlandValentina Allmann, Daniela Dyntar, Dirk Lehnick, et al.
Lung Cancer (Amsterdam, Netherlands)|September 17, 2013
Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenibOliver Gautschi, Solange Peters, Vincent Zoete, et al.
Psycho-Oncology|February 10, 2026
Psychosocial Support Needs and Utilization of Support Among Survivors of Cancer in Young Adulthood in Switzerland: A Report From the Adolescent and Young Adult (AYA) Psychosocial Health StudyCéline Bolliger, Martina Ospelt, Marcel Blum, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 18, 2016
A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 TestingKlazien Matter-Walstra, Matthias Schwenkglenks, Stefan Aebi, et al.
European Journal of Dermatology : EJD|January 17, 2018
Nivolumab for recurrent cutaneous squamous cell carcinoma: three casesVeronika Blum, Beat Müller, Silvia Hofer, et al.
Pageof 10

Showing results (21-30 of 91) with videos related to

Sort By:
Pageof 10
Lung Cancer (Amsterdam, Netherlands)|July 4, 2016
MicroRNA-106a targets autophagy and enhances sensitivity of lung cancer cells to Src inhibitorsSacha I Rothschild, Oliver Gautschi, Jasmin Batliner, et al.
Future Oncology (London, England)|February 5, 2014
Crizotinib inhibits migration and expression of ID1 in MET-positive lung cancer cells: implications for MET targeting in oncologyEmanuel Stutz, Oliver Gautschi, Martin F Fey, et al.
Clinical Lung Cancer|May 8, 2009
Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer: current status and new directionsOliver Gautschi, Philip C Mack, Angela M Davies, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2008
Aurora kinases as anticancer drug targetsOliver Gautschi, Jim Heighway, Philip C Mack, et al.
Lung Cancer (Amsterdam, Netherlands)|August 17, 2010
The stem cell gene "inhibitor of differentiation 1" (ID1) is frequently expressed in non-small cell lung cancerSacha I Rothschild, Andreas Kappeler, Daniel Ratschiller, et al.
Swiss Medical Weekly|February 14, 2023
Overall survival and role of programmed death ligand 1 expression in patients with metastatic non-small-cell lung cancer and immunotherapy: an observational study from central SwitzerlandValentina Allmann, Daniela Dyntar, Dirk Lehnick, et al.
Lung Cancer (Amsterdam, Netherlands)|September 17, 2013
Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenibOliver Gautschi, Solange Peters, Vincent Zoete, et al.
Psycho-Oncology|February 10, 2026
Psychosocial Support Needs and Utilization of Support Among Survivors of Cancer in Young Adulthood in Switzerland: A Report From the Adolescent and Young Adult (AYA) Psychosocial Health StudyCéline Bolliger, Martina Ospelt, Marcel Blum, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 18, 2016
A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 TestingKlazien Matter-Walstra, Matthias Schwenkglenks, Stefan Aebi, et al.
European Journal of Dermatology : EJD|January 17, 2018
Nivolumab for recurrent cutaneous squamous cell carcinoma: three casesVeronika Blum, Beat Müller, Silvia Hofer, et al.
Pageof 10